Biomedical subjects

Glenn Reynolds

Publications and source records attributed to Glenn Reynolds.

3 recordsLinked to original sources

PubMed2006

Faster flow quantification using sensitivity encoding for velocity-encoded cine magnetic resonance imaging: in vitro and in vivo validation.

PURPOSE: To test the agreement between conventional and sensitivity-encoded (SENSE) velocity encoded cine (VEC) MRI in a flow phantom and in subjects with congenital and acquired heart disease. MATERIALS AND METHODS: Flow measurements were performed in a 1.5 T scanner using a segmented k-space VEC MRI sequence and then repeated with a SENSE factor of 2. The flow phantom used a piston pump to generate physiologic arterial waveforms (0.5-4.9 L/min). In the subjects, flow measurements were performed in the ascending aorta (N = 33) and/or the main pulmonary artery (N = 24). RESULTS: Utilization of SENSE reduced the scan time by 50%. In the phantom, measurements without and with SENSE agreed closely with a mean difference of 0.01 +/- 0.08 L/min or 0.12% +/- 3.8% (P = 0.68). In the subjects, measurements without and with SENSE also agreed closely with a mean difference of 0.08 +/- 0.36 L/min or 1.3% +/- 7.2% (P = 0.08). Compared with standard imaging, the use of SENSE reduced the signal-to-noise ratio (SNR) by 28% in the phantom (N = 10) and 27% in vivo (N = 22). CONCLUSION: VEC MRI flow measurements with a SENSE factor of 2 were twice as fast and agreed closely with the conventional technique in vitro and in vivo. VEC MRI with SENSE can be used for rapid and reliable quantification of blood flow.

Adolescent↗

PubMed2006

Characterization of microvascular dysfunction after acute myocardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium enhancement imaging.

PURPOSE: While both first-pass perfusion and late gadolinium enhancement by cardiovascular magnetic resonance (CMR) can assess coronary microvascular status in acute myocardial infarction (AMI), there are only limited data on their respective diagnostic utility. We aim to evaluate: the utility of first-pass perfusion and late gadolinium enhancement imaging in the detection and quantification of microvascular dysfunction after reperfused acute myocardial infarction, using TIMI frame count (TIMI FC) as the reference standard of microvascular assessment; and their relationship with infarct size and ventricular function. METHODS: First-pass perfusion and late gadolinium enhancement imaging were performed in 25 consecutive AMI patients (84% men, age 58 +/- 10) within 72 h of successful reperfusion. We assessed the myocardial extent of microvascular dysfunction using the size of the perfusion defect on first-pass perfusion (PD%) and the hypoenhanced core region within late gadolinium enhancement (MDEcore%). PD%, MDEcore%, and TIMI FC were analyzed independently of each other and with blinding to clinical data. We adjusted PD% and MDEcore% to the myocardial mass subtended by the infarct-related artery according to the 16-segment model. RESULTS: Median infarct size involved 13.9% (interquartile range: 8.5 to 22.2%) of the left ventricle and median left ventricular ejection fraction was 52% (interquartile range: 43 to 61%). PD% demonstrated evidence of microvascular dysfunction more frequently (84% vs. 36% of patients, p < 0.002) and involved a larger myocardial extent (23.5 +/- 17.5% vs. 3.5 +/- 7.7%, p < 0.001) compared to MDEcore%. PD% had strong correlations with TIMI FC (Spearman rho = 0.62, p < 0.001) and infarct size (rho = 0.64, p < 0.001), and a moderate correlation with LVEF (rho = -0.39, p = 0.055). MDEcore% also correlated with TIMI FC (rho = 0.54, p = 0.005) and infarct size (rho = 0.52, p < 0.01) but not with LVEF (p = NS). CONCLUSIONS: PD% appeared to provide a stronger noninvasive assessment of the microvascular function than MDEcore% and correlated well with prognostic markers such as left ventricular ejection fraction and infarct size. Future studies should consider quantitative analyses of both first-pass perfusion and late gadolinium enhancement imaging in the evaluation of novel therapies targeted to the microvasculature of the infarct-related artery.

Aged↗

PubMed2003

Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T.

BACKGROUND AND PURPOSE: Theoretically, proton ((1)H) MR spectroscopy at a higher field strength has the advantages of higher signal-to-noise ratio and improved spectral resolution. We therefore compared the ability of single-voxel (1)H MR spectroscopy at 1.5 and 3 T to diagnostically discriminate among cognitively normal elderly subjects, patients with mild cognitive impairment (MCI), and patients with Alzheimer disease (AD). METHODS: At both 1.5 and 3 T, we studied 41 cognitively normal elderly subjects, 20 patients with MCI, and 20 patients with AD. In each subject, (1)H MR spectroscopy was performed at TEs of 30 and 135 ms and from voxels placed over the posterior cingulate gyri. RESULTS: Average line widths and interexamination variability of metabolite ratios were higher at 3 T than at 1.5 T. Consistent quantification of glutamine (Gln) + glutamate/creatine (Cr) and Gln/Cr peak ratios occurred at 3 T but not at 1.5 T. Choline (Cho)/Cr (at TE = 135 ms) and myo-inositol (MI)/Cr were higher and N-acetylaspartate (NAA)/Cr (at TE = 135 ms) and NAA/MI were lower in patients with MCI than in cognitively normal subjects only at 1.5 T. MI/Cr and Cho/Cr were higher and NAA/Cr and NAA/MI were lower in patients with AD than in cognitively normal subjects at both 1.5 and 3 T. Differentiation of patients with AD from cognitively normal subjects by using the NAA/MI data was similar at both field strengths (P >.05). CONCLUSION: With currently available technology, the diagnostic performance of (1)H MR spectroscopy in patients with MCI and those with AD was not better at 3 T than at 1.5 T.

Aged↗